Dr. James Krell
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,055
Licensed in Alabama since 1993, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
AL license 17253 (first issued 1993; active) · GA license 33617
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Total Skin and Beauty Dermatology Center, PC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,055
- Services billed
- 5,953
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 2,364 | 468 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,015 | 817 |
| Destruction of precancer skin growth, 1 growth | 776 | 615 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 509 | 126 |
| Biopsy of related skin growth, first growth | 321 | 282 |
| Destruction of skin growth, 1-14 growths | 295 | 262 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 261 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 200 | 166 |
| Ultrasonic guidance for placement of radiation therapy fields | 185 | 13 |
| Established patient office or other outpatient visit, 10-19 minutes | 140 | 133 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Betamethasone Dipropionate Other prescribers in Birmingham, AL | 270 |
| Doxycycline Hyclate Other prescribers in Birmingham, AL | 260 |
| Clobetasol Propionate Other prescribers in Birmingham, AL | 185 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Birmingham, AL | 166 |
| Tacrolimus Other prescribers in Birmingham, AL | 134 |
| Dutasteride Other prescribers in Birmingham, AL | 125 |
| Methotrexate (methotrexate sodium) Other prescribers in Birmingham, AL | 122 |
| Dupixent Syringe (dupilumab) Other prescribers in Birmingham, AL | 111 |
| Dupixent Pen (dupilumab) Other prescribers in Birmingham, AL | 93 |
| Cephalexin Other prescribers in Birmingham, AL | 90 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 206 payments worth $127,347 in total to this clinician.
| Galderma Laboratories, L.P. | $30,656 |
|---|---|
| AbbVie Inc. | $19,913 |
| Sun Pharmaceutical Industries Inc. | $17,592 |
| UCB, Inc. | $15,533 |
| Lilly USA, LLC | $15,316 |
| Regeneron Healthcare Solutions, Inc. | $11,936 |
| Janssen Biotech, Inc. | $9,136 |
| Pfizer Inc. | $4,900 |
| Compensation for services other than consulting (speaking, faculty) | $95,652 |
|---|---|
| Speaking at a medical education program | $13,718 |
| Travel and Lodging | $9,295 |
| Consulting Fee | $4,725 |
| Food and Beverage | $3,863 |
| Education | $94.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,425 |
| Galderma Laboratories, L.P. Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Regeneron Healthcare Solutions, Inc. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,843 |
| Pfizer Inc. Oct 9, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $4,725 |
| Janssen Biotech, Inc. Feb 15, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| UCB, Inc. May 30, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $4,000 |
| Lilly USA, LLC Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $4,000 |
| Sun Pharmaceutical Industries Inc. Jun 25, 2025 | Speaking at a medical education program ILUMYA · Dermatology | $3,971 |
All 66 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 30, 2025 | Education TREMFYA · Immunology · in-kind | $94.99 |
| Janssen Biotech, Inc. Nov 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,800 |
| UCB, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $1,725 |
| Sun Pharmaceutical Industries Inc. Nov 4, 2025 | Speaking at a medical education program ILUMYA · Dermatology | $3,249 |
| Pfizer Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) CIBINQO · Inflammation & Immunology | $76.51 |
| Lilly USA, LLC Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Pfizer Inc. Oct 9, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $4,725 |
| Lilly USA, LLC Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Lilly USA, LLC Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $2,000 |
| Lilly USA, LLC Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,750 |
| Lilly USA, LLC Sep 30, 2025 | Travel and Lodging travel to CORINTH, MS · in-kind | $1,064 |
| Lilly USA, LLC Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Galderma Laboratories, L.P. Sep 19, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Lilly USA, LLC Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Galderma Laboratories, L.P. Sep 11, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to HUNTSVILLE, AL · in-kind | $975 |
| Galderma Laboratories, L.P. Sep 11, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to HUNTSVILLE, AL · in-kind | $30.00 |
| AbbVie Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $1,938 |
| Galderma Laboratories, L.P. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Aug 7, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to TUSCALOOSA, AL · in-kind | $875 |
| Galderma Laboratories, L.P. Aug 7, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to TUSCALOOSA, AL · in-kind | $30.00 |
| Regeneron Healthcare Solutions, Inc. Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| Regeneron Healthcare Solutions, Inc. Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $835 |
| Galderma Laboratories, L.P. Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $600 |
| AbbVie Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $2,325 |
| Regeneron Healthcare Solutions, Inc. Jul 22, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| Regeneron Healthcare Solutions, Inc. Jul 7, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to DETROIT, MI 48242, MI · in-kind | $14.00 |
| Lilly USA, LLC Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $4,000 |
| Sun Pharmaceutical Industries Inc. Jun 25, 2025 | Speaking at a medical education program ILUMYA · Dermatology | $3,971 |
| Sun Pharmaceutical Industries Inc. Jun 25, 2025 | Travel and Lodging ILUMYA · Dermatology · travel to Montgomery, AL · in-kind | $975 |
| Regeneron Healthcare Solutions, Inc. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,843 |
| Lilly USA, LLC Jun 17, 2025 | Travel and Lodging EBGLYSS · Immunology · travel to IRVING, TX | $12.00 |
| Galderma Laboratories, L.P. Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Regeneron Healthcare Solutions, Inc. Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| Lilly USA, LLC Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| Galderma Laboratories, L.P. Jun 5, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to HUNTSVILLE, AL · in-kind | $1,050 |
| Lilly USA, LLC Jun 5, 2025 | Travel and Lodging travel to IRVING, AL · in-kind | $456 |
| Regeneron Healthcare Solutions, Inc. Jun 5, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to DETROIT, MI · in-kind | $256 |
| Galderma Laboratories, L.P. Jun 5, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to HUNTSVILLE, AL · in-kind | $30.00 |
| UCB, Inc. May 30, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $4,000 |
| UCB, Inc. May 30, 2025 | Travel and Lodging Bimzelx · Immunology · travel to Birmingham, AL | $33.36 |
| Galderma Laboratories, L.P. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| UCB, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $1,725 |
| UCB, Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $1,725 |
| UCB, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $1,725 |
| Amgen Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $1,625 |
| Janssen Biotech, Inc. Apr 19, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $900 |
| Galderma Laboratories, L.P. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| AbbVie Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,875 |
| Regeneron Healthcare Solutions, Inc. Apr 11, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to DETROIT, MI · in-kind | $653 |
| Lilly USA, LLC Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,000 |
| UCB, Inc. Apr 8, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $1,380 |
| AbbVie Inc. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,875 |
| Sun Pharmaceutical Industries Inc. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) ILUMYA · Dermatology | $1,440 |
| Sun Pharmaceutical Industries Inc. Apr 2, 2025 | Travel and Lodging ILUMYA · Dermatology · travel to Birmingham, AL | $11.34 |
| Sun Pharmaceutical Industries Inc. Mar 27, 2025 | Speaking at a medical education program ILUMYA · Dermatology | $3,249 |
| UCB, Inc. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $1,725 |
| Sun Pharmaceutical Industries Inc. Mar 27, 2025 | Travel and Lodging ILUMYA · Dermatology · travel to Tuscaloosa, AL · in-kind | $579 |
| Sun Pharmaceutical Industries Inc. Mar 27, 2025 | Travel and Lodging ILUMYA · Dermatology · travel to Tuscaloosa, AL · in-kind | $391 |
| AbbVie Inc. Mar 26, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $776 |
| Janssen Biotech, Inc. Mar 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,800 |
| AbbVie Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $5,425 |
| AbbVie Inc. Feb 26, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $1,087 |
| Sun Pharmaceutical Industries Inc. Feb 25, 2025 | Speaking at a medical education program ILUMYA · Dermatology | $3,249 |
| Janssen Biotech, Inc. Feb 15, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| UCB, Inc. Feb 13, 2025 | Compensation for services other than consulting (speaking, faculty) Bimzelx · Immunology | $1,380 |
| Galderma Laboratories, L.P. Feb 10, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $2,700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 26 industry-funded studies in 2025, from 8 companies. The companies reported $349,889 in research payments for these studies, mostly to the institutions running them.
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Sun Pharmaceutical Industries Inc. - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie Inc. · Recruiting · NCT06012240 - TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 60 weeks of treatment with a withdrawal and retreatment period
Takeda Pharmaceuticals U.S.A., Inc. - A phase 4, multicenter, open-label, single-arm study to investigate the efficacy of lebrikizumab in adult and adolescent participants with atopic dermatitis with limited body surface area involvement and high itch bur…
Eli Lilly and Company - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)
Janssen Research & Development, LLC - M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)
AbbVie Inc. - Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
E.r. Squibb & Sons, L.l.c. · Completed · NCT04036435 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
AbbVie Inc. · Completed · NCT06333860
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.